How a disrupted gut microbiome quietly fuels cancer development

Trillions of microorganisms living in the human gut do far more than help digest food. When that microbial community falls out of balance, a state researchers call dysbiosis, the consequences may extend well beyond bloating and irregular digestion. A 2026 review published in Surgical and Experimental Pathology by Durre Aden, Kamlesh Darji, and Sufian Zaheer lays out the accumulating evidence that gut dysbiosis contributes to cancer initiation, promotion, and progression through at least three converging pathways: chronic inflammation, altered metabolite production, and suppression of immune surveillance.

Dysbiosis, chronic inflammation, and oncogenic DNA damage

Healthy gut microbiota produce a steady supply of short-chain fatty acids (SCFAs), compounds made when bacteria ferment dietary fiber. SCFAs, especially butyrate, feed the cells lining the colon and suppress inflammation. Dysbiosis flips that chemistry. Reduced microbial diversity cuts SCFA output, weakening the epithelial barrier and leaving inflammatory signals unchecked. The review describes how that chronic, low-grade inflammation creates the conditions for cellular damage, genomic instability, and the kinds of oncogenic mutations that start a cancer.

Genotoxic pressure comes from multiple directions at once. Secondary bile acids, including deoxycholic acid and chenodeoxycholic acid, accumulate when dysbiotic bacteria process bile salts incorrectly; both compounds induce DNA strand breaks and generate reactive oxygen species. Nitrosamines, formed through microbial metabolism of certain dietary compounds, add further mutagenic load. Meanwhile, butyrate's dual role is striking: in normal colonocytes it suppresses proliferation by inhibiting histone deacetylase enzymes, but cancerous colonocytes preferentially burn glucose instead, sidestepping that protective effect entirely. These mechanisms parallel findings reviewed across gastrointestinal cancers more broadly, where genotoxicity, metabolic dysregulation, and epigenetic modification appear repeatedly as shared threads.

Specific bacteria that drive colorectal and gastric cancer

Several organisms emerge from the review as particularly well-characterized cancer promoters. Fusobacterium nucleatum, long associated with colorectal tumors, uses a surface protein called FadA adhesin to bind E-cadherin on epithelial cells, triggering NF-kB activation and helping the tumor evade immune detection. Colibactin-producing strains of Escherichia coli, designated pks+, inflict DNA double-strand breaks directly on host cells.

Helicobacter pylori remains the most extensively studied microbial carcinogen. Its virulence proteins CagA and VacA disrupt cell polarity and adhesion, induce reactive oxygen species, and inactivate the tumor-suppressor gene RUNX3 through both proteasome degradation and promoter hypermethylation. Enterotoxigenic Bacteroides fragilis produces a toxin that stimulates Wnt signaling and pro-inflammatory cascades. The list extends to oral cancers as well, with Porphyromonas gingivalis, Prevotella species, and Aggregatibacter actinomycetemcomitans each linked to inflammation and immune suppression in oral squamous cell carcinoma. The breadth of implicated organisms underscores that oncogenic dysbiosis is not a single-bug problem.

Lifestyle, environment, and the microbiome inputs that tip the balance

The review catalogs the upstream factors that push a microbiome toward dysbiosis in the first place. Diets high in saturated fats reduce populations of Bifidobacterium and Lactobacillus while promoting bacteria that generate carcinogenic metabolites like hydrogen sulfide. The Western diet specifically encourages nitrosamine formation. Conversely, plant-based diets rich in fiber support microbial diversity and SCFA production.

Beyond diet, chronic stress elevates cortisol and reduces beneficial bacteria; physical inactivity is independently associated with lower microbial diversity; irregular sleep disrupts circadian rhythms in ways that compromise the gut epithelial barrier and allow microbial products to leak into systemic circulation. Antibiotics, when used indiscriminately, eliminate beneficial species and open ecological space for resistant and potentially pathogenic organisms. Environmental pollutants, including heavy metals and pesticides, push the microbiome toward a pro-inflammatory state. Even artificial sweeteners such as aspartame and saccharin appear to negatively affect microbial composition. Host genetics add another layer: variations in genes including NOD2, ATG16L1, and CLR/CARD9 shape how the immune system reads microbial signals and influence susceptibility to inflammatory disorders that precede cancer. Research on hormone-driven cancers suggests the microbiome's influence extends through endocrine pathways as well, with gut bacteria modulating estrogen availability in ways that may affect breast and endometrial cancer risk.

Open questions about microbiome causality and the limits of current data

The review is candid about what remains unresolved. Almost all the mechanistic detail comes from cell culture experiments and animal models; longitudinal human studies, the kind needed to establish that dysbiosis precedes and causes cancer rather than simply accompanying it, are largely absent from the current literature. The authors call for mechanistic validation of microbiota-host interactions in human cohorts and for standardized protocols that can produce reproducible results across research groups. A persistent challenge in microbiome research is that changes in bacterial abundance alone cannot reliably identify which species are protective and which are harmful, a problem that demands large-scale prospective studies with consistent methodology before clinical translation can proceed safely.

Immune evasion is another area where the picture is incomplete. Dysbiotic microbiota appear to expand populations of regulatory T cells and myeloid-derived suppressor cells, helping tumors avoid immune clearance, but the precise signaling sequences involved are not yet mapped in humans.

Probiotics, FMT, and microbiome-targeted cancer strategies

Despite those gaps, the therapeutic possibilities are attracting serious attention. Fecal microbiota transplantation, which transfers stool from a healthy donor to restore microbial balance, has already proven effective for recurrent Clostridioides difficile infections and is now being explored in oncology contexts. Probiotics that competitively exclude pathogens and boost SCFA output represent a lower-risk intervention, and prebiotic fibers that selectively feed beneficial bacteria offer another lever. Phage therapy, which uses viruses that target specific bacterial strains, could allow more precise correction of dysbiosis without the broad collateral damage caused by conventional antibiotics.

Emerging evidence positions gut microbes as regulators of how well patients respond to chemotherapy, immunotherapy, and radiotherapy, which means that restoring microbial balance before or during treatment could amplify therapeutic efficacy. Computational models and AI are beginning to identify microbiome-derived biomarkers that might one day guide precision oncology decisions, selecting treatments based partly on a patient's microbial profile. The review by Aden, Darji, and Zaheer frames all of this as promising but premature: the science of deliberately reshaping the microbiome to prevent or treat cancer is advancing quickly, but the safe, validated translational strategies still need to be built.

Evidence rating

EMERGING — 71/100

Caveats:

• This is a narrative review, not an original study — it synthesizes existing literature but generates no new data.
• Most cited mechanisms come from preclinical or observational research; direct causation in humans has not been established for many of the pathways described.
• Funding was not disclosed by the authors.
• The field lacks large-scale longitudinal human trials; the authors themselves note this as a key gap.

Narrative review synthesizing preclinical, observational, and mechanistic literature on gut dysbiosis and carcinogenesis. No original human data are presented; causal claims rest on associations and animal or in vitro mechanistic studies. The authors acknowledge the absence of large longitudinal human trials as a central limitation.

References

1. Durre Aden, Kamlesh Darji, Sufian Zaheer (2026). Cancer and the gut microbiome: the oncogenic impact of dysbiosis. Surgical and Experimental Pathology. https://doi.org/10.1186/s42047-026-00244-5
2. Sarbjeet Kaur Makkar, Kumar S. Bishnupuri (2025). The gut microbiome and gastrointestinal cancers: mechanisms, biomarkers and therapeutic opportunities. Frontiers in Physiology. https://doi.org/10.3389/fphys.2025.1676796
3. Exian Mou, Rui Guo, Yong Yi, Yang Li, Yutang Yao, Jia Xu (2026). Beyond estrobolome 1.0: unraveling endocrine-microbiome axis as a driver and therapeutic target in hormone-driven cancers. npj Biofilms and Microbiomes. https://doi.org/10.1038/s41522-026-01074-9
4. Current insights and challenges when studying the human gut microbiome – PMC. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056529/
5. Lingshan Liao, Mengying Zeng, Debei Liu, Yuxing He, Wei Du, Yanlin Cao (2025). Focus on gut microbes: new direction in cancer treatment. Frontiers in Oncology. https://doi.org/10.3389/fonc.2025.1505656
6. Miriam Tudorache, Andreea-Ramona Treteanu, Gratiela Gradisteanu Pircalabioru, Irina-Oana Lixandru-Petre, Alexandra Bolocan, Octavian Andronic (2025). Gut Microbiome Alterations in Colorectal Cancer: Mechanisms, Therapeutic Strategies, and Precision Oncology Perspectives. Cancers. https://doi.org/10.3390/cancers17142294